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ABSTRACT  36 
Background: Pyrazolones are the most common cause of selective NSAIDs 37 
hypersensitivity. We studied a large group of patients with immediate and delayed 38 
selective responses to metamizole. 39 
Methods: Patients with suspicion of hypersensitivity to metamizole were evaluated. We 40 
verified acetylsalicylic acid-tolerance and classified patients as immediate or delayed 41 
responders if they showed symptoms less or more than 24hours after metamizole 42 
administration. Skin tests were performed and if negative, basophil activation test 43 
(BAT) was performed on immediate responders. If this was negative, we performed a 44 
drug provocation test (DPT) with metamizole. 45 
Results: A total of 137 patients were included: 132 reacted within 24 hours (single 46 
NSAID-induced urticaria/angioedema/anaphylaxis; SNIUAA); 5 after 24 hours (single-47 
NSAID-induced delayed hypersensitivity reactions; SNIDHR). More specifically, 48 
73.72% reacted within 30 minutes; 9.48% 30-60 minutes; 6.56% 1-2 hours; 6.56% 2-8 49 
hours and 3.64% after over 24 hours. Most SNIUAA patients developed anaphylaxis 50 
(60.60%); for SNIDHR, maculopapular exanthema was the most frequent entitiy (60%). 51 
Skin testing was positive for 62.04% of all cases and BAT for 28% of SNIUAA patients 52 
with negative skin tests. In 5.1% cases DPT with metamizole was needed for 53 
establishing diagnosis. In the 22.62% of cases, diagnosis was established by a consistent 54 
and unequivocal history of repeated allergic episodes in spite of negative skin test and 55 
BAT.   56 
Conclusions: SNIUAA to metamizole is the most frequent type of selective NSAID 57 
hypersensitivity, with anaphylaxis being the most common clinical entity. It may occur 58 
over an hour after drug intake. SNIDHR occurs in a very low percentage of cases. The 59 
low sensitivity of diagnostic tests may be due to incomplete characterization of the 60 
chemical structures of metamizole and its metabolites. 61 
62 
INTRODUCTION  63 
Adverse drug reactions constitute an important public health issue, causing 3 to 6% of 64 
all hospital admissions and occurring in 10 to 15% of hospitalized patients [1]. Non-65 
steroidal anti-inflammatory drugs (NSAID) are the most frequent medicines involved in 66 
drug hypersensitivity reactions in both adults [2] and children [3] followed by beta-67 
lactam antibiotics [4]. Hypersensitivity reactions to NSAIDs have been classified into 68 
different categories depending on the clinical symptoms induced, the number of 69 
NSAIDs involved and the presence or absence of underlying disease [5]. The following 70 
classification has been proposed: 1) NSAID-exacerbated respiratory disease (NERD); 2) 71 
NSAID-exacerbated cutaneous disease (NECD); 3) NSAID-induced 72 
urticaria/angioedema (NIUA); 4) Single NSAID-induced 73 
urticaria/angioedema/anaphylaxis (SNIUAA); and 5) Single-NSAID-induced delayed 74 
hypersensitivity reactions (SNIDHR). 75 
The mechanism involved in the first three reaction types is thought to be non-76 
immunologically mediated (cross-hypersensitivity) but related to the inhibition of the 77 
cyclooxygenase (COX-1) enzyme [5]. The last two categories involve an 78 
immunologically-mediated response that is induced by a single drug/drug-group, with 79 
subjects tolerating other chemically unrelated compounds (selective response) including 80 
strong COX-1 inhibitors [5, 6]. In SNIUAA, symptoms usually occur shortly after drug 81 
intake [5] and an IgE-mediated mechanism has been proposed [7-10]. In SNIDHR, 82 
reactions occur 24–48 h or longer after drug intake [5] and a T cell-mediated 83 
mechanism is likely [11]. As occurs with BL antibiotics, symptoms may appear at a 84 
shorter interval after drug intake [12, 13]. 85 
Most studies of hypersensitivity reactions to NSAIDs have focused on non-86 
immunologically mediated reactions (cross-hypersensitivity) [14-17], mainly in NERD, 87 
although there is growing interest in the cutaneous entities (NIUA and NECD) [14-19]. 88 
Although immunologically mediated reactions account for 25-30% of all NSAID 89 
hypersensitivity reactions [20], less attention has been paid to these reactions and no 90 
studies have been performed looking at large series of well-phenotyped cases. It is 91 
known that pyrazolones, particularly metamizole ([N-(1,5-dimethyl-3-oxo-2-92 
phenylpyrazolin-4-yl)-N-methylamino] methanesulfonate, drug bank id. no. DB04817), 93 
are the most frequent drugs involved in immunologically mediated reactions [7, 20, 21]. 94 
Their use is widespread in many countries due to their analgesic, antipyretic and 95 
spasmolytic properties and therefore many patients are exposed. 96 
Our aim was to study a large group of patients who developed selective responses (SR) 97 
to metamizole, one of the most frequently used analgesics in our population, and to 98 
establish in how many cases responses were immediate or delayed, following the 99 
classification provided by ENDA group [5]. The contribution of diagnostic tests (both in 100 
vivo and in vitro) was also assessed.  101 
102 
METHODS 103 
Patients  104 
We evaluated patients with symptoms suggestive of hypersensitivity reactions to 105 
metamizole referred to the allergy unit of the University Regional Hospital of Málaga 106 
(Málaga, Spain) and Infanta Leonor Hospital (Madrid, Spain) over a period of 3 years 107 
(2012-2014).  108 
 109 
Inclusion criteria. Patients aged 14–80 years with a confirmed diagnosis of SR to 110 
metamizole.  111 
The diagnosis was established according to the algorithm shown in Figure 1. The first 112 
approach was to verify tolerance to acetylsalicylic acid (ASA) if this was not known. If 113 
subjects responded to ASA, they were considered cross-hypersensitive to NSAIDs and 114 
not included in this study. If subjects tolerated ASA in a drug provocation test (DPT), 115 
they were considered as having either immediate reactions when they had the symptoms 116 
less than 24 hours after metamizole administration, or as delayed reactions when 117 
symptoms occurred more than 24 hours later. Skin tests with metamizole were 118 
performed for patients with both immediate and delayed reactions as described 119 
previously [22]. In patients with immediate reactions, if skin tests were negative, a 120 
basophil activation test (BAT) with metamizole was carried out. If skin tests or BAT 121 
were positive, the patients were confirmed as having SR to metamizole. If both skin test 122 
and BAT were negative, we considered the number of episodes suffered after 123 
metamizole administration: if the patient had at least 2 episodes, they were diagnosed as 124 
having SR to metamizole, but if the patient had only one episode, a positive DPT with 125 
metamizole was required, except in subjects with severe reactions (e.g. toxic epidermal 126 
necrolysis or anaphylactic shock).  127 
Exclusion criteria. Patients younger than 14 years or older than 80 years of age; patients 128 
with a confirmed diagnosis of cross-hypersensitivity to NSAIDs; patients with one 129 
reported prior reaction to metamizole, with negative skin test and BAT results, where 130 
DPT with metamizole was contraindicated; patients who tolerated metamizole; patients 131 
where DPT to COX-1 inhibitor is contraindicated due to underlying disease; pregnant or 132 
breastfeeding patients; patients taking beta-blockers or ACE inhibitors or with 133 
contraindications for epinephrine administration; patients who had acute infections 134 
and/or underlying cardiac, hepatic or renal diseases that contraindicated DPT; and 135 
subjects with psychosomatic disorders. 136 
 137 
Clinical history 138 
Patients were questioned about the symptoms induced by metamizole administration; 139 
the time interval between drug intake and reaction onset; the number of episodes; the 140 
time interval between the last reaction and study; underlying nasal and bronchial 141 
symptoms, food allergy and the presence of underlying chronic spontaneous urticaria, 142 
either active or in remission. 143 
 144 
Atopy status assessment 145 
The atopy status was assessed with skin prick test (SPT) performed with a battery of 20 146 
common inhalant allergens, including pollens, house dust mites, moulds and animal 147 
danders and a battery of 31 common food allergens that included animal, fruit and 148 
vegetable allergens (ALK, Madrid, Spain). Histamine hydrochloride 10 mg/mL and 149 
phenolated glycerolsaline were used as positive and negative controls, respectively. A 150 
positive SPT response was defined as a wheal diameter of 3 mm or larger to at least one 151 
of these allergens. The patients were requested to stop taking any medications that 152 
contained antihistamine at least 8 days before skin testing.  153 
 154 
Skin testing 155 
For immediate reactions, skin prick and intradermal (ID) tests were carried out as 156 
described [22] using metamizole (Boehringer Ingelheim, Barcelona, Spain) at 40 and 157 
400 mg/mL for SPT and at 0.4 and 4 mg/mL for ID. For those cases reporting severe 158 
reactions, ID was initially performed using 0.004 and 0.04 mg/ml. An increase in the 159 
diameter of the wheal by more than 3 mm, 20 min after testing was considered positive 160 
for SNIUAA. 161 
For delayed reactions, patch and ID tests were carried out and evaluated after 48 hours 162 
as described [22]. For ID tests, the presence of intradermal papular induration after 48h 163 
was considered positive. Patch tests were performed by mixing powdered metamizole in 164 
petrolatum at 10% w/w. The occlusion time was 48h. Erythema with oedema, papules, 165 
vesicles or bullae 48 and/or 72 h after testing was considered positive [22]. 166 
 167 
Basophil activation test 168 
In patients with a suspected immediate reaction, BAT was performed as described [23] 169 
using metamizole (Boehringer Ingelheim, Barcelona, Spain) at 0.25 and 2.5 mg/mL. 170 
Results were considered positive when the stimulation index (SI), calculated as the ratio 171 
of the percentage of degranulated basophils with the different haptens to the negative 172 
control, was greater than 2 in at least one of the concentrations used.  173 
 174 
Oral drug provocation test 175 
In order to verify tolerance to a strong COX-1 inhibitor, DPT with ASA was performed 176 
in a single blind manner, as described [20]: placebo capsules were given at different 177 
times on the first day, three doses of ASA were administered orally at intervals of 90 178 
min (5, 30, 100 mg) on the second day, and, if negative, another two doses of ASA 179 
(150, 300 mg) on the third day. If patient had only one episode after metamizole 180 
administration and no contraindications for DPT existed, increasing doses of 181 
metamizole were administered orally at intervals of 90 min for 2 days (first day: 5, 10, 182 
50 mg; accumulative dose 65 mg; 2nd day: 50, 150, 300 mg; accumulative dose 500 183 
mg).  184 
If cutaneous and/or respiratory symptoms or alterations in vital signs (rhythm 185 
alterations, decrease in peak expiratory flow (PEF) rate or hypotension) appeared, the 186 
procedure was stopped and the symptoms were evaluated and treated. If no symptoms 187 
appeared during drug administration, the therapeutic dose of ASA/metamizole was 188 
achieved. If tolerance occurred, this was followed by 2 days/8 hours at maximum dose, 189 
after a gap of 24 hours. ASA, metamizole and placebo were given in opaque capsules 190 
prepared by the hospital pharmacy service. 191 
Forced expiratory volume in 1s values had to be at least 80% of predicted values, with 192 
an absolute value of at least 1.5 L. Antihistamine agents were stopped 1 week before 193 
challenge. 194 
 195 
Statistical analysis 196 
Data analysis was performed using Chi-squared analysis to test differences in nominal 197 
variables between groups, the Fisher test was used when there were no criteria for using 198 
the chi-square test and the Mann–Whitney test was used for quantitative variables. All 199 
reported p-values represented two-tailed tests, with values <0.05 considered statistically 200 
significant. The analysis included age, gender, atopic status, number of episodes, 201 
clinical manifestations and methods used for the diagnosis. 202 
The study was conducted according to the principles of the Declaration of Helsinki and 203 
approved by the Ethics Committees of the University Regional Hospital of Málaga. All 204 
the participants were informed orally about the study and signed the corresponding 205 
informed consent. 206 
207 
RESULTS  208 
A total of 5926 patients with a clinical history of drug hypersensitivity reactions were 209 
evaluated at the Allergy units of the University Regional Hospital of Málaga and the 210 
Infanta Leonor Hospital in Madrid in 2012-2014. NSAIDs were involved in 2398 cases. 211 
In 922 cases metamizole was the NSAID involved in the episodes. Of these, a total of 212 
137 patients were confirmed as having SR to metamizole and were included in this 213 
study. The remaining 785 patients with reactions after metamizole intake were not 214 
considered for this study due to cross-hypersensitivity (678 subjects) or unconfirmed 215 
diagnosis (107 subjects). Of these, 6 were pregnant; 101 had negative skin and BAT and 216 
could not undergo DPT to ASA and/or metamizole (40 were older than 70 years and 217 
had cardiopulmonary co-morbidities, 41 reported anaphylactic shock and 20 severe 218 
delayed reactions)  219 
The 137 patients with confirmed SR to metamizole included in this study had a median 220 
age of 53 years [interquartile range (IR): 41–64] and 101 were women (73.72%). Fifty-221 
seven cases (41.6%) were atopic and 35 (25.54%) had rhinitis, 10 (7.29%) had asthma, 222 
10 (7.29%) had symptoms attributed to food allergy and 7 (5.1%) had underlying 223 
chronic urticaria.  224 
Considering the total group and according to clinical history (see Table 1), most cases 225 
with confirmed SR to metamizole developed anaphylaxis (80; 58.39%), followed by 226 
urticaria (42, 30.65%), angioedema (7, 5.1%), maculopapular exanthema (MPE) (3, 227 
2.18%), fixed drug eruption (FDE) (2, 1.45%) and glottis oedema, exanthema with 228 
bullae and exanthema with skin desquamation with only one patient each (0.7%). 229 
Concerning the number of previously reported episodes, patients had a median of 2 (IR: 230 
1-2). Analyzing the time interval between metamizole administration and the onset of 231 
the reactions reported in clinical history, in a total of 101 (73.72%) patients the reaction 232 
occurred within 30 minutes; in 13 (9.48%) patients within 30-60 minutes; in 9 (6.56%) 233 
within 1-2 hours; in 9 (6.56%)  within 2-8 hours and in 5 (3.64%)  more than 24 hours 234 
later. For further analysis, we classified patients as SNIUAA if the time interval was 235 
less than 24 hours after metamizole administration (132; 96.35%) and SNIDHR if the 236 
interval was more than 24 hours (5; 3.64%).  237 
Considering the patients with anaphylaxis (n=80), in all cases there was skin 238 
involvement. We show the involvement of other organs in table 2. The respiratory 239 
involvement consisted of dyspnea, wheezing and chest tightness, the gastrointestinal 240 
consisted of abdominal cramps, vomiting and diarrhoea and the cardiovascular 241 
consisted of tachycardia and hypotension. 242 
Analyzing the time interval in the cases of anaphylaxis, in 70 (87.5%) the reactions 243 
occurred in less than 30 minutes, in 6 (7.5%) between 30-60 minutes, in 2 (2.5%) 244 
between 1-2 hours and in 2 (2.5%) between 2-8 hours. No cases of anaphylaxis 245 
occurred beyond this time. 246 
According to clinical history, most cases reported to have taken metamizole by oral 247 
route and 5 by intravenous one. In 2 patients there were one episode after intravenous 248 
administration and another after oral intake. In all cases, the reactions reported by the 249 
patient were more severe with the involvement of 4 organ systems (skin, respiratory, 250 
cardiovascular and gastrointestinal or transitory loss of consciousness) when the 251 
metamizole was administered by intravenous route (see table 2). In the 5 cases where 252 
the reactions occurred after intravenous administration, the symptoms appeared within 253 
30 minutes.  254 
No differences were found in age, gender, atopy, rhinitis, asthma, food allergy, 255 
underlying chronic urticaria and number of episodes reported when comparing 256 
SNIUAA and SNIDHR.  257 
Most SNIUAA patients (80; 60.60%) had anaphylaxis whilst amongst SNIDHR patients 258 
the most frequent clinical entity was MPE (3; 60%).  259 
The median time interval between the last reaction and the study was 6 months (IR: 3-260 
24). No differences were found between SNIUAA and SNIDHR. 261 
Of the 137 cases evaluated, 85 (62.04%) subjects gave positive skin tests (see Table 3). 262 
For SNIUAA, 37 (28.03%) were positive by prick-test and 45 (47.36%) by ID. For 263 
SNIDHR, 3 (60%) were positive by both ID and patch test (see table 2). One patient 264 
developed an immediate systemic response during SPT with metamizole although the 265 
reading was negative. In SNIUAA patients with negative skin test results (n=50), BAT 266 
with metamizole was performed, and was positive in 14 subjects (28%).  267 
Comparing patients with positive and negative results in skin tests and BAT, the time 268 
interval between the last reaction induced by metamizole and the study was shorter in 269 
those who had positive tests (3 (IR: 3-12) vs 12 (IR: 3-36) months, p=0.023).  270 
The results of DPT with metamizole are shown in Table 4. A total of 6 cases reported 271 
immediate reactions after metamizole administration, had negative skin tests and BAT 272 
and only one episode induced by metamizole; 1 case reported  a delayed reaction after 273 
metamizole administration, had negative skin tests and only one episode induced by 274 
metamizole. In all cases DPT with metamizole induced mild symptoms: 7 patients 275 
developed pruritus and wheals localized on different parts of the body and 1 MPE with 276 
no systemic symptoms. No patient had respiratory or cardiovascular system 277 
involvement. The patients responded to a median dose of 480 (IR: 65-575) mg of 278 
metamizole. The symptoms disappeared within 1-48h of administering antihistamine 279 
and corticosteroid treatment.  280 
In 31 patients (22.62%) with both negative skin tests and BAT, the diagnosis was 281 
achieved by clinical history as they had 2 or more episodes induced by metamizole and 282 
tolerance to ASA was confirmed by DPT (see Table 3). 283 
284 
DISCUSSION 285 
We have evaluated a large group of cases with hypersensitivity to pyrazolones 286 
following the consensus guidelines published by the EAACI special interest group on 287 
NSAID hypersensitivity reactions [5]. After excluding cross-hypersensitive subjects we 288 
verified, in those confirmed SR cases, how many were SNIUAA and SNIDHR. 289 
The diagnosis of SR patients is often complex, not risk-free, and requires trained 290 
personnel and specific resources [24]. In this study we first verified tolerance to ASA in 291 
order to exclude patients with cross-hypersensitivity to NSAIDs. Of the remaining 292 
cases, those with positive skin tests and/or BAT were confirmed as SR to metamizole, 293 
as reported previously by our group [23]. Cases with negative skin tests and BAT 294 
required a minimum history of two previous reactions after metamizole administration 295 
to be considered SR. Although in previous studies looking at cross-hypersensitivity to 296 
NSAIDs at least three episodes were required [18], in SR we have considered 2 clear 297 
episodes to be sufficient, provided that clinical history was reliable. Those patients with 298 
both negative skin tests and BAT that reported only one reaction after metamizole 299 
administration and contraindications for DPT were excluded from this study. This could 300 
contribute to some bias in this study in terms of the sensitivity of the skin tests, 301 
particularly for those with immediate reactions.   302 
Skin testing was positive for 62.04% of the cases tested. Of the remaining cases (n=52), 303 
28% of SNIUAA could be identified by BAT. The overall sensitivity including both 304 
tests was therefore 72.26%. Skin and in vitro tests have shown variable results in 305 
different studies [23, 25-27]. For immediate reactions Gamboa et al. [25] reported BAT 306 
sensitivity to be 42.3% and specificity 100%. Similar results were observed in a later 307 
study by Gomez et al. [23] in which the sensitivity of the BAT was 54.9% and the 308 
specificity 85.7%, and 62% of patients had positive skin tests to metamizole. In this 309 
study we cannot establish the overall sensitivity of the tests because we did not perform 310 
BAT with metamizole in all patients. The time interval between the reaction and the 311 
study can affect the outcome of the tests [23] as has been shown in subjects with 312 
immediate hypersensitivity reactions to beta-lactams [28, 29]. We found differences 313 
comparing the time interval between the reaction and the performance of the tests in 314 
those who were negative and those who were positive. Another factor to take into 315 
account that can contribute to the low sensitivity of diagnostic tests is the incomplete 316 
characterization of the chemical structures of metamizole and its metabolites [30]. Four 317 
major metamizole metabolites have been described in the literature [31], however we 318 
recently demonstrated the presence of arachidonoyl metabolites in patients receiving 319 
metamizole [32], and additional metabolites, such as oxalic acid derivatives have been 320 
reported elsewhere [33]. It cannot be ruled out that in some patients, metamizole 321 
metabolites may contribute to hypersensitivity reactions. 322 
Considering the underlying mechanism in patients with immediate SR to pyrazolone 323 
derivatives, evidence (basophil activation and skin test positivity) supports an IgE 324 
mediated mechanism [7, 23]. There are only a few experimental studies on the 325 
quantification of IgE antibodies and no detailed studies have been carried out in this 326 
field [8-10]. For delayed reactions, positive delayed intradermal and/or patch tests to the 327 
culprit drug with a characteristic T cell infiltrate have been reported [6, 34-38]. Further 328 
evidence has been provided by in vitro cellular assays [38, 39].  329 
In the case of beta-lactams, the time interval between drug administration and the 330 
appearance of symptoms is considered crucial for evaluating allergic reactions [40]. The 331 
reactions to these drugs can be considered immediate and non-immediate. The former 332 
are induced by an IgE-mediated response, whilst for the latter, there are some 333 
controversies as to the underlying mechanism, especially for those cases where there is 334 
an interval of between 1 and 24 hours after drug intake [41]. It has been shown that, for 335 
the so called accelerated reactions to amoxicillin, occurring between 1 and 6 hours, the 336 
mechanism is not IgE-dependent [13]. In fact, some evidence indicates that these 337 
reactions are T cell-mediated [12]. However, to our knowledge this mechanism has not 338 
yet been studied for NSAIDs. In this study, by analysing the time interval between 339 
metamizole administration and reaction onset, we observed that 13% of patients had 340 
reactions 1-24 hours after metamizole intake. When analysing basophil activation in 341 
those cases where the reaction occurred 1-8 hours after metamizole administration, we 342 
did not find any positive response in a group of 8 patients tested, suggesting that an IgE 343 
mechanism is unlikely. The time interval between drug administration and the onset of 344 
the reaction may be related to the production of different, as yet unidentified, 345 
metabolites. Metamizole metabolism occurs rapidly following intake and some of the 346 
resultant metabolites are measurable in serum, urine and other biological fluids shortly 347 
after administration [42, 43]. 348 
 349 
Metamizole has more than 20 known metabolites [31] formed by either alkaline 350 
hydrolysis or biotransformation, however only a few studies have analysed their 351 
immunogenic potential [8, 44]. The identification of the adequate metabolite may be 352 
necessary to identify the underlying mechanisms and better diagnose these patients. 353 
The percentage of atopy is high in these patients, but less than for cross-hypersensitive 354 
ones [20]. Atopy prevalence was similar in both SNIUAA and SNIDHR, however more 355 
SNIDHR cases are needed to confirm this.   356 
In summary, we conclude that pyrazolones contribute to the production of selective 357 
reactions to NSAIDs, of which most are immediate. Although skin tests and BAT may 358 
aid in the diagnosis of these reactions, further research is needed to help identify the 359 
culprit metabolite and develop better diagnostic tools. To our knowledge this is the 360 
largest study of cases with allergic responses to pyrazolones to date. 361 
362 
Table 1.  363 
 SNIUAA               
n=132 
SNIDHR               
n=5 
Age yr (IR) 53 (41.25-63) 68 (31.75-75.75) 
Gender n (%) female/n(%) male 97 (73.48)/35 (26.51) 4(80)/1(20) 
Number of episodes reported 
after metamizole 
administration 
2 (1-2) 2 (2-3) 
Clinical 
entities       
n (%) 
Anaphylaxis    80 (60.60) 0 
Urticaria          42 (31.81) 0  
Angioedema     7 (5.3) 0  
Glottis oedema  1 (0.75) 0 
FDE                   2 (1.51 0 
MPE                 0 3 (60) 
Exanthema with 
bullae        
0 1 (20) 
Exanthema with 
skin 
desquamation        
0 1 (20) 
  364 
365 
Table 2.  366 
367 













Skin+transitory loss of consciousness 
n=22 (27.5%) 
Oral 
Skin+respiratory+transitory loss of consciousness 
n=9 (11.25%) 
Oral 
Skin+gastrointestinal+transitory loss of consciousness 
n=9 (11.25%) 
Oral 
Skin+respiratory+gastrointestinal+transitory loss of consciousness 
n=2 (2.5%) 
Oral 






Table 3.  368 
Methods for diagnosis 
SNIUAA   
n=132 
SNIDHR     
 n=5 
Skin test                 
Prick test     37 (28.03%) Not done 
ID                   45 (47.36%) 3(60%) 
Patch        Not done 3 (60%) 
BAT  14 (28%) Not done 
DPT with metamizole  6 (12%) 1 (20%) 
Clinical history+DPT ASA 30 (60%) 1 (20%) 
369 










Patient 1 46/F Urticaria 30 65 
Generalized pruritus and 
facial angioedema 
Patient 2 41/F Urticaria+angioedema 45 575 
Pruritus in hands and wheals 
in thorax and abdomen 
Patient 3 42/F Urticaria 60 205 
Systemic pruritus, 
conjunctival injection and 
tongue oedema 
Patient 4 33/M Urticaria+angioedema 30 575 
Wheals in abdomen plus 
pruritus 
Patient 5 43/M Urticaria 45 65 
Pruritus in thorax, arms and 
back and wheals in thorax 
Patient 6 52/F Urticaria 720 480 
Facial angiodema and 
pruritus and wheals in thorax 




Maculopapular exanthema in 
trunk 
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